Biodol Therapeutics, a biotech company, aims at developing first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified a specific receptor (FLT3) as a key pain component for triggering and maintaining the chronic neuropathic pain (NP) state. Biodol Therapeutics also discovered that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces the opioid doses while maintaining the opioid efficacy and avoiding its mid-term side effects on CP. The development of molecules, intra- or extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics (5 patents).
Biodol Therapeutics is a well-experienced Team:
Dr. Fabien GRANIER (CEO), 15 years of experience in setting up and managing innovative companies and in managing innovation funding levers;
Dr. Pierre SOKOLOFF (Chairman of the SAB), former director of Exploratory R&D in Neurology-Psychiatry at Pierre Fabre Laboratories;
Dr. Bernard PAU (Business Development), former Director of the Department of Life Sciences of the CNRS;
Prof. Jean VALMIER (SAB), discovered the patented mechanism at Institut des Neurosciences in Montpellier;
Dr. Didier ROGNAN (SAB), Deputy Director of the Laboratory of Therapeutic Innovation in Strasbourg.